Roche inks deal with Blueprint worth up to $1.7 billion for cancer drug

This post was originally published on this site

ZURICH (Reuters) – Swiss drugmaker Roche will pay up to $1.7 billion to Blueprint Medicines to help develop and commercialise a new treatment for people with so-called RET-altered cancers that have mutations that drive tumour growth. Roche will pay …

Click here to read full article